Purpose: Some drug products contain phthalates as excipients, and in vitro studies have demonstrated that phthalates interfere with cellular mechanisms involved in colorectal cancer development. We therefore examined the association between cumulative phthalate exposure from drug products and risk of colorectal adenocarcinomas. 
| INTRODUCTION
The widespread use of phthalates as softeners in plastic products has gained increasing attention since phthalates are suspected endocrine disruptors and reproductive toxins. 1 Although the carcinogenic properties of phthalates are still uncharacterized, some epidemiologic studies have associated ortho-phthalate exposure with incident breast cancer in humans. 2, 3 Ortho-phthalates are known to stimulate the epithelial-tomesenchymal transition necessary for cancer invasion and metastasis, mediated by histone deacetylase 6. 4 In vitro studies support a role of phthalates in mechanisms of colon carcinogenesis. Additionally, a dose-dependent effect of ortho-phthalates on aryl hydrocarbon receptor (AhR) function has been suggested. The AhR is a transcription factor that plays an important role in cell proliferation and differentiation and in tumor development. 5 Some phthalates are used as excipients in pharmaceuticals. Their water resistant and acid stable properties are utilized in the pharmaceutical production of sustained or delayed release preparations. 6 Among users of phthalate-containing drugs, an up to 50-fold increased urinary concentration of phthalate metabolites was demonstrated compared with nonusers. 7 The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are aware of the potential harmful phthalate exposure from pharmaceutical preparations, and both agencies have published guidelines on limiting pharmaceutical phthalate exposure from orally administered drug products. 8, 9 Recent population-based Danish data suggest that exposure to phthalates from drugs is not negligible, with a median dibutyl phthalate (DBP) exposure from prescription drugs that remained above
European regulatory limit of exposure. 10, 11 This led us to consider if the phthalate exposure from orally administered drugs carries an excess risk of developing colorectal adenocarcinomas. We therefore performed a Danish nationwide registrybased case-control study to examine the association between cumulative pharmaceutical phthalate exposure and risk of colorectal adenocarcinoma.
| METHODS AND MATERIALS
The study was conducted according to STROBE guidelines for reporting observational studies, 12 using a nationwide case-control approach investigating the cumulative phthalate exposure from orally administered drug products among individuals diagnosed with colorectal cancer (cases) and population-based cancer-free persons (controls). Lastly, patients with total colectomy were excluded.
| Data sources
Controls were selected using risk set sampling, applying the same exclusion criteria as for cases. For each case, we selected 10 cancerfree controls among all Danish residents of the same gender and birth year. Controls were identified through the civil registration system covering all Danish inhabitants, 13 and they were assigned an index date identical to that of the corresponding case. Subjects were eligible for being sampled as controls before they became cases.
KEY POINTS
• Some prescription drugs contain phthalates.
• Exposure may be significant.
• Little is known about the carcinogenic properties of phthalates.
• Omitting NSAID use, major exposure to phthalates was associated with a slightly increased risk of colorectal adenocarcinoma.
• Findings are unlikely of clinical relevance. We aimed to separate the risk among those exposed to low amounts of phthalates from those exposed to larger amounts and still provide sufficient number of subjects within each category to produce meaningful estimates.
| Exposure definition
High exposure to any ortho-phthalate was defined as greater than 500 mg of cumulative phthalate exposure, intermediate exposure was
defined as 250 to 499 mg of cumulative exposure, and low exposure was defined as less than 250 mg of cumulative exposure over the study period. For enteric phthalate polymers, the corresponding categories were greater than 10 000, 5000 to 9999, and less than 4999 mg of cumulative exposure. Never-exposed groups were defined for ortho-phthalates and enteric phthalate polymers.
| Confounding variables
The following potential confounders were identified and incorporated 
| Main analysis
The analysis followed a conventional matched case-control approach.
We tabulated the frequency and proportion of cases and controls within categories of the exposures and covariates. We used conditional logistic regression to estimate ORs for colorectal adenocarcinoma associated with high exposure to any ortho-phthalate, DEP, and DBP or to any enteric phthalate polymer, adjusting for potential confounders. We performed dose-response analyses using abovementioned predefined exposure groups. In all analyses, exposure to any phthalate was compared with never-exposure (reference category).
In all exposure calculations, we disregarded prescriptions redeemed 
| Other
The study was approved by the Danish Data Protection Agency.
According to Danish law, studies based solely on register data do not require approval from an ethics review board. 21 
| RESULTS
We identified 25 814 colorectal cancer cases with histologically verified colorectal adenocarcinoma eligible for inclusion ( Figure 1 ).
To these cases were matched 258 140 cancer-free population controls. Most of the included cases and controls were above 70 years of age (51%), and 56 % were men. For ortho-phthalate exposure, drug use, comorbidities, and educational level, the cases and controls were balanced. Baseline characteristics of cases and controls are shown in Table 1 .
Overall, 6607 (25.6%) of cases had used phthalate-containing orally administered drugs compared with 68 600 (26.6%) of controls.
Among these, 674 cases (2.6%) and 7724 controls (2.9%) were classified as having high exposure to ortho-phthalates. This yielded an adjusted OR of 0.89 (95% CI, 0.81-0.96) for the association between high ortho-phthalate exposure and the risk of colorectal adenocarcinoma (Table 2) .
Dose-dependent effect was not seen across exposure levels among those exposed to any ortho-phthalate (P = 0.63, test for trend).
There were no apparent associations for exposure below 500 mg.
Analyses of specific phthalate exposures consistently returned estimates below the null across levels of DEP and DBP with cumulated exposure exceeding 250 mg (Table 2) . Likewise, inverse associations were seen in analyses stratified by age, gender, cancer location, and stage of disease.
Excluding patients diagnosed with diabetes, patients treated with lithium, patients treated with ASA products, and patients treated for alcohol abuse did not alter our findings (Table 3) ). An equivalent pattern of was seen for HPMCP, but not for CAP and PVAP (Table S1 ).
Changing the lag time to either 6 months or 2 years had no effect on our estimates when compared with 1-year lag (data not shown).
| DISCUSSION
In this study, Danish users of phthalate-containing drug products with cumulated exposure to any ortho-phthalate exceeding 500 mg across the study period appeared less likely to develop colorectal adenocarci- analysis excluding NSAID users led to a reversal of the association, indicating a positive association between phthalate exposure and colorectal cancer risk.
Use of high-quality registries covering the entire Danish population is the main strength of our study. In addition, primary nonadherence was eliminated by the use of dispensed prescriptions. 22 Additionally, the influence of secondary nonadherence was reduced, because exposure was quantified in cumulative amount. Patients missing doses of their medications often stretch the coverage of their prescription. In this way, these patients are exposed to the entire amount of phthalates from the dispensed product. 23 The principle weakness of this study is lack of information on lifestyle factors known to influence the risk of colorectal adenocarcinomas such as smoking, 24 alcohol consumption, 25 body weight, 26 and certain diets. 24 While we controlled for a number of possible confounders and covariates, we cannot exclude confounding by indication. The distribution of quantitative phthalate exposure by drug is listed in Tables S2 and S3 . Quantitatively, the most important contributions to the cumulative ortho-phthalate exposure were from preparations containing lithium, multienzymes, theophylline, erythromycin, and diclofenac (Tables S2 and S3 ).
Our primary finding was in direct opposition to our hypothesis as data suggested a protective effect rather than representing a risk factor.
Estrogenic activity of ortho-phthalates could be a plausible biological explanation supporting a protective effect of phthalates towards colorectal cancer. Subgroup analysis omitting NSAID exposed individuals eliminated the protective association and even suggested a slightly increased risk from high cumulative ortho-phthalate exposure. As this finding emerges from a post hoc analysis, interpretation of this result should be made with caution. We believe the most plausible explanation for our primary result is substantial confounding from NSAID use. NSAID exposure is known to reduce the risk of colorectal cancers, 20 which could explain the protective effect observed. Ibuprofen, diclofenac, naproxen, and ketoprofen were available as phthalatecontaining variants throughout the study period, and NSAID products represented 14.9% of DEP exposure and 0.9% of DBP exposure (Tables   S2 and S3) . No phthalate-containing aspirin products were available.
The quantitatively most important contribution to DBP exposure was from preparations with lithium. About 50% of lithium reimbursed in the study period contained ortho-phthalate, 10,11 but neither depression nor lithium itself appear associated with increased risk of colorectal cancer.
27,28
Based on the currently available data, the US Consumer Product period, only 2.6% of cases and 3.0% of controls in this study were exposed to more than 500 mg of ortho-phthalate from prescription drugs. Compared with environmental exposure, the cumulated exposure from prescription drugs during the study period is of modest magnitude in most of the subjects included in this study. However, some users of phthalate-containing drug products are highly exposed, and their exposure might be markedly higher than exposure from environmental sources. 11 The estimate of minimum environmental exposure to DEP and DBP exceeds 1200 mg throughout the study 35, 36 Additionally, information on a specific source of exposure for up to 11 years is rather limited, considering that most humans are exposed to phthalates from environmental sources, throughout their entire lifetime.
| CONCLUSION
An apparent overall slightly protective effect of cumulative phthalate exposure from drug excipients for colorectal adenocarcinoma was demonstrated. Omitting NSAID users from the analysis reversed the signal and suggested a slightly increased risk associated with high cumulative exposure to ortho-phthalates. Regardless of assumptions on causality, the signals are weak and unlikely to be of meaningful clinical relevance.
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